LungLife AI, Inc.

LSE LLAI.L

LungLife AI, Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.37

LungLife AI, Inc. Price to Book Ratio (P/B) is 0.37 on January 14, 2025, a -85.91% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

LungLife AI, Inc. 52-week high Price to Book Ratio (P/B) is 2.60 on January 15, 2024, which is 609.72% above the current Price to Book Ratio (P/B).
LungLife AI, Inc. 52-week low Price to Book Ratio (P/B) is 0.35 on December 20, 2024, which is -4.87% below the current Price to Book Ratio (P/B).
LungLife AI, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 0.94.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

LSE: LLAI.L

LungLife AI, Inc.

CEO	Dr. Paul Pagano Ph.D.
IPO Date	July 8, 2021
Location	United States
Headquarters	2545 West Hillcrest Drive
Employees	8
Sector	Technology
Industries Artificial Intelligence (AI) Biotechnology

Description

LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.

Key trends

Past 5 years